Five years of experience with hydroxyurea in children and young adults with sickle cell disease.
about
Systematic review: Hydroxyurea for the treatment of adults with sickle cell diseasePatient-specific blood rheology in sickle-cell anaemia.Patient-specific modeling of individual sickle cell behavior under transient hypoxia.Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).Hydroxyurea treatment of children with hemoglobin SC disease.Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG).Effective control of sickle cell disease with hydroxyurea therapy.How I use hydroxyurea to treat young patients with sickle cell anemia.Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization.National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008.Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa).The role of hydroxyurea in sickle cell disease.Therapeutic challenges in childhood sickle cell disease. Part 1: current and future treatment options.Therapeutic challenges in childhood sickle cell disease. Part 2: a problem-orientated approach.Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)."Sickle Cell Disease in the Emergency Department: Atypical Complications and Management"Pharmacotherapy in sickle cell disease--state of the art and future prospectsSurvival and mortality among users and non-users of hydroxyurea with sickle cell disease.Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?Myocardial ischaemia in children with sickle cell diseaseMassive accidental overdose of hydroxyurea in a young child with sickle cell anemiaManagement of sickle cell disease in primary care.Decision analysis of treatment strategies in children with severe sickle cell disease.Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension studyGum Arabic as fetal hemoglobin inducing agent in sickle cell anemia; in vivo study.No improvement in suboptimal vitamin A status with a randomized, double-blind, placebo-controlled trial of vitamin A supplementation in children with sickle cell disease.Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.The genomics of new drugs in sickle cell disease.Hydroxyurea for children with sickle cell diseaseThe prevention and management of stroke in sickle cell anaemia.Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease.Sickle cell disease in North Europe.Barriers to hematopoietic cell transplantation clinical trial participation of african american and black youth with sickle cell disease and their parents.Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation.Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease.The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease.Current strategies for the management of children with sickle cell disease.
P2860
Q24610970-FFF39C04-7459-406B-882E-B6EF73DB2EC9Q30691183-3E17810C-E3AC-4603-ADAF-DF421835C248Q30843061-94A1D5C3-B8F5-41F3-B90A-6782EF137D62Q33345042-A8235D18-6A73-4BC6-A3B0-55F44ADC2649Q33403128-554D995C-EBC4-491B-B326-FDE42A6A2857Q33484805-4B7C6385-AFA7-48E7-B967-8D9AEAA7416EQ33913096-334D6372-61C7-4BCC-82F8-1E252DD1C460Q33985120-910561DA-14A3-42DC-B00A-2D32FFB90034Q34026647-7E17CCE7-ED16-4B79-92A2-B29633D94F50Q34253814-25591CFA-31B9-4A66-97D3-EDC3C1FED6C3Q35034032-0B7E6D5D-E309-451C-875C-7ED9B881A4A9Q35050928-312453CE-9EAE-4913-AA2B-07F2F55CFA17Q35076604-0D0CEC62-76BB-41BA-B500-6F66C463993DQ35076607-EE2498AE-2C43-4BB6-8D3C-465E0FE94267Q35097294-AF379D80-2D97-435F-A9FC-6DAA31A1E99AQ35212165-F3B6E33C-4153-4B4B-94BF-92273C52A52DQ35220342-D5B165E6-8B45-4845-B14D-A2659CFD6FD1Q35222814-06910DF6-1111-4D89-82FF-EF1D29ED90C4Q35234959-06348731-001E-4527-AC86-3353DD185167Q35278821-6CCDF9EF-30D6-4119-8CC2-C9710FDC5DD1Q35353627-D456100C-25BF-4931-A2EA-36D05D3BF578Q35611782-D866CA90-149A-432A-8842-67A293B32E6EQ35800106-AC893D74-ACFC-4113-B202-0522E938EAC0Q35848253-2F9645A1-79AB-4CE7-A9BD-7D7AC681D741Q35882386-34289590-FB6D-4B3C-92D2-C74D82E9EB1BQ36231661-EE2269B6-9710-460D-AEED-EF38D00C151CQ36243884-E35D3AD1-EAD0-4F58-8C00-CCE4CB82B12DQ36596719-9311F6F8-0AAB-4DAE-AD1C-A81C99D9C5ACQ36612962-05BDA09C-E92C-41BF-A459-50A20DF26E7FQ36627220-249BA774-C24C-4DC1-AB93-58F75DB299E6Q36742702-6D3B4296-11D9-49A2-9C9F-2AA233F12058Q36762093-0F34FB0E-8788-4F4B-BD35-B687984ED20AQ36860550-A06FB33A-D2A3-42BF-AB4F-A8AB2F276A8FQ37008748-15E1282C-3E14-407B-B03F-8B7B31812199Q37223344-E2A55B59-6E2A-4E24-9CF6-3D3A4E314427Q37258852-51CA51BB-4CE9-436B-86F7-B5EBD2E09B58Q37367662-B6C294A7-3E2A-437D-85A3-73A0F0FA4641Q37480741-B7A81906-6A28-4224-8836-89FC311D86F5Q37677221-B3B777E7-4F1B-4B6E-B0F7-C73A7A084DFDQ37810082-3931434B-7941-4F94-A604-89C3B5CE04C8
P2860
Five years of experience with hydroxyurea in children and young adults with sickle cell disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Five years of experience with ...... ults with sickle cell disease.
@en
Five years of experience with ...... ults with sickle cell disease.
@nl
type
label
Five years of experience with ...... ults with sickle cell disease.
@en
Five years of experience with ...... ults with sickle cell disease.
@nl
prefLabel
Five years of experience with ...... ults with sickle cell disease.
@en
Five years of experience with ...... ults with sickle cell disease.
@nl
P2093
P1433
P1476
Five years of experience with ...... ults with sickle cell disease.
@en
P2093
Feremans W
Hunninck K
Philippet P
Sturbois G
P304
P356
10.1182/BLOOD.V97.11.3628
P407
P577
2001-06-01T00:00:00Z